Kapidin

Lercanidipine, the active ingredient in Kapidin, is a calcium channel blocker presented as an oral tablet for systemic use. It is employed to manage elevated blood pressure in adult patients requiring antihypertensive therapy.

GNH USA supplies Kapidin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to treat hypertension, a condition characterized by chronically elevated arterial pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure, helping to achieve target levels. - Secondary hypertension: assists in controlling blood pressure when it is caused by underlying disorders. - Isolated systolic hypertension: lowers high systolic readings, particularly in older adults.

Lercanidipine may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic injury: signs of liver dysfunction such as jaundice. - Allergic reaction: rash, itching, or swelling. - Angioedema: swelling of face, lips, or throat. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy with Kapidin, certain precautions should be observed.

- Blood pressure monitoring: regularly assess to ensure therapeutic response. - Hepatic impairment: use with caution in patients with liver dysfunction. - Abrupt discontinuation: avoid stopping suddenly to prevent rebound hypertension. - Elderly patients: start at lower doses and monitor for dizziness. - Hypersensitivity: contraindicated in individuals with known allergy to lercanidipine or related compounds. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Concomitant antihypertensives (e.g., ACE inhibitors, ARBs): additive blood‑pressure‑lowering effect. - Grapefruit juice: can elevate drug concentrations.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: watch for excessive bradycardia. - Digoxin: observe for signs of toxicity.